menu
    • menu
    [{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Indian Council of Medical Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indian Council of Medical Research \/ Inapplicable"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Indian Council of Medical Research \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Indian Council of Medical Research \/ Bharat Biotech"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indian Council of Medical Research \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Indian Council of Medical Research \/ University of Oxford"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Aurigene Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Council of Medical Research \/ Indian Council of Medical Research","highestDevelopmentStatusID":"4","companyTruncated":"Indian Council of Medical Research \/ Indian Council of Medical Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Indian Council of Medical Research

    Menu

    Indian Council of Medical Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desidustat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Zydus Lifesciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus and ICMR Start Phase 2 Desidustat Trial in Sickle Cell Disease

                            Details : Rytstat (desidustat), first-of-its-kind oral tablet being investigated for the treatment for Sickle Cell Disease, in India.

                            Product Name : Oxemia

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2024

                            Lead Product(s) : Desidustat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Zydus Lifesciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Aurigene Oncology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ICMR partners with industry leaders for groundbreaking First-in-Human Phase-1 cl ..

                            Details : Under the partnership, ICMR will engage in collaborative research on a small molecule for multiple myeloma with Aurigene oncology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Aurigene Oncology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            No Merit Seen in Including Paxlovid in Covid Treatment: ICMR

                            Details : Paxlovid (nirmatrelvir) is an orally bioavailable protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.

                            Product Name : Paxlovid

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 05, 2022

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Baricitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Call for Expression of Intent to Participate as a Study Site for India-UK RECOVERY

                            Details : Baricitinib will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 14, 2021

                            Lead Product(s) : Baricitinib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Covid-19: Bharat Biotech Begins Phase 3 Trials of Covaxin in India

                            Details : India’s first phase 3 efficacy study for a Covid-19 vaccine, and the largest phase III efficacy trial ever conducted in India. Trial volunteers will receive two intramuscular injections of Covaxin, about 28 days apart.

                            Product Name : Covaxin

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Convalescent Plasma Misses the Mark in Phase 2 Trial

                            Details : The study results showed that Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            India Begins Human Trials of its First Homegrown Coronavirus Vaccine

                            Details : The Indian Council of Medical Research have allowed both Phase 1 and 2 human trials of Covaxin, the experimental vaccine developed by Bharat Biotech. Lokesh Sharma, the Council’s media coordinator.

                            Product Name : Covaxin

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 21, 2020

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 15, 2020

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Bharat Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed

                            Indian Council of Medical Research

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ICMR Partners with Bharat Biotech to Launch COVID-19 Vaccine

                            Details : For covaxin, Bharat Biotech has joined with the National Institute of Virology, part of the Indian Council of Medical Research. The company is separately developing COVID-19 vaccine candidates in collaboration with Thomas Jefferson University and the Uni...

                            Product Name : Covaxin

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 07, 2020

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth